1. Canada Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Nirvana Life Sciences Inc

Nirvana Life Sciences Inc

CCSE:NIRV.X
0.05
CAD
0.00
(0.00%)
-0.02EPS
1.60MMarket Cap
Nirvana Life Sciences Inc
CSE:NIRV.X
(Canadian Securities Exchange)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CAD
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.04
- -
-0.1
-0.08
-1.55
-0.44
-0.19
-0.08
-0.02
Basic EPS, GAAP
-0.02
-0.01
-0.01
-0.05
-0.13
-0.1
-0.04
-0.01
-0.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.23
-0.22
-0.16
- -
-0.05
-0.28
-0.23
-0.31
-0.03
Book Value per Share
-0.23
-0.22
-0.16
- -
-0.05
-0.28
-0.23
-0.31
-0.03
Tangible Book Value per Share
3
3
3
3
4
3
5
5
18
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-6
-1
-1
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1
-1
-1
- -
-1
-1
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-1
-1
-1
- -
- -
-1
-1
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-3.19
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

CAD

•

in mil. unless spec.
Jul'26
Oct'26
Jan'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
2
3
2

Working Capital

CAD

•

in mil. unless spec.
Jul'26
Oct'26
Jan'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
268.56%
30.84%
Free Cash Flow
- -
146.32%
-63.41%
Net Income, GAAP
- -
385.96%
-58.03%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
-0.03
-0.05
-0.07
-0.19
2025
-0.01
-0.01
-0.02
-0.04
-0.08
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Nirvana Life Sciences Inc. engages primarily in the development, manufacturing, and distribution of natural health products, supplements, and botanical therapeutics. The company's core product offerings include dietary supplements, natural extracts, personalized health and wellness formulations, and nutraceutical products, designed to support immune health, cognitive function, metabolic health, and overall wellness. Nirvana Life Sciences incorporates cutting-edge botanical research and quality manufacturing processes to develop proprietary formulas and plant-based health solutions. The company targets health-conscious consumers, healthcare practitioners, and retail distributors across North America, with expanding reach into international markets. Founded in 2016 and headquartered in British Columbia, Canada, Nirvana Life Sciences has built a strategic focus on natural health innovation and product efficacy. Recently, within the past 1-2 years, the company has embarked on significant business expansions including new product launches in advanced botanicals and enhanced nutraceutical formulas. Additionally, Nirvana Life Sciences has entered strategic partnerships with leading research institutions to accelerate botanical research and expand its product development capabilities. The company has also made operational enhancements to scale its manufacturing processes and widen market distribution channels, adapting to growing consumer demand for natural health products. Nirvana Life Sciences operates in the natural health and wellness industry, including business segments such as nutritional supplements, botanical extracts, and wellness product manufacturing. Its product portfolio is branded under proprietary label formulations and marketed directly and through partners to retail health stores, e-commerce platforms, and wellness professionals. The company continues to invest in innovation, compliance, and market expansion to strengthen its position in the growing global natural health sector. No recent name changes or corporate reorganizations have been reported as of the latest available data. Overall, Nirvana Life Sciences Inc. delivers an integrated suite of natural health products emphasizing botanical efficacy, manufacturing quality, and strategic growth initiatives aligned with contemporary health trends and consumer preferences. This positions the company as a dynamic player focused on advancing natural health solutions within Canada and internationally.